Interleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis

NCT06447701 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

486

Enrollment

OTHER

Sponsor class

Conditions

Brain Diseases
Ischemic Stroke
Ischemia
Stroke
Cerebral Infarction
Atherosclerosis of Artery
Atheroscleroses, Intracranial

Interventions

DRUG: Tocilizumab
DRUG: NaCl 0.9% 100ml

Sponsor

Zhujiang Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]